HK1214831A1 - 新型融合分子及其應用 - Google Patents

新型融合分子及其應用

Info

Publication number
HK1214831A1
HK1214831A1 HK16102746.5A HK16102746A HK1214831A1 HK 1214831 A1 HK1214831 A1 HK 1214831A1 HK 16102746 A HK16102746 A HK 16102746A HK 1214831 A1 HK1214831 A1 HK 1214831A1
Authority
HK
Hong Kong
Prior art keywords
fusion molecules
novel fusion
novel
molecules
fusion
Prior art date
Application number
HK16102746.5A
Other languages
English (en)
Inventor
Doron Lipson
Roman Yelensky
Joel Robert Greenbowe
Jie He
Original Assignee
Found Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Found Medicine Inc filed Critical Found Medicine Inc
Publication of HK1214831A1 publication Critical patent/HK1214831A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK16102746.5A 2012-11-05 2016-03-09 新型融合分子及其應用 HK1214831A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722533P 2012-11-05 2012-11-05
US201361763442P 2013-02-11 2013-02-11
PCT/US2013/068604 WO2014071419A2 (en) 2012-11-05 2013-11-05 Novel fusion molecules and uses thereof

Publications (1)

Publication Number Publication Date
HK1214831A1 true HK1214831A1 (zh) 2016-08-05

Family

ID=49627083

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102746.5A HK1214831A1 (zh) 2012-11-05 2016-03-09 新型融合分子及其應用

Country Status (7)

Country Link
US (2) US11230589B2 (zh)
EP (2) EP2914622B1 (zh)
AU (4) AU2013337264B2 (zh)
CA (1) CA2890346A1 (zh)
ES (1) ES2949394T3 (zh)
HK (1) HK1214831A1 (zh)
WO (1) WO2014071419A2 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SG2014012728A (en) 2011-08-23 2014-06-27 Foundation Medicine Inc Novel kif5b-ret fusion molecules and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
MX365214B (es) 2012-03-08 2019-05-27 Astellas Pharma Inc Nuevo producto de fusion de fgfr3.
US20150191791A1 (en) * 2012-07-05 2015-07-09 Lsip, Llc Fgfr2 fusion gene
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
EP2945652B1 (en) * 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2014165710A2 (en) * 2013-04-05 2014-10-09 Life Technologies Corporation Gene fusions
CN105658814A (zh) * 2013-08-20 2016-06-08 日本国立癌症研究中心 在肺癌中检测出的新型融合基因
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2015066439A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating hematological malignancies
US10048277B2 (en) * 2014-01-24 2018-08-14 Japanese Foundation For Cancer Research Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
US20170114415A1 (en) * 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
WO2015191666A2 (en) * 2014-06-10 2015-12-17 Blueprint Medicines Corporation Raf1 fusions
CA2956962A1 (en) * 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
US20190083521A1 (en) * 2014-09-17 2019-03-21 Epizyme, Inc. Combination therapy for treating cancer
KR20220162823A (ko) * 2014-09-26 2022-12-08 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
JP2018027019A (ja) * 2014-11-26 2018-02-22 国立研究開発法人国立がん研究センター 胆道がんにおける新規治療標的融合遺伝子
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3258923A4 (en) 2015-02-19 2019-01-16 Mayo Foundation For Medical Education And Research METHODS AND SUBSTANCES FOR EVALUATING RESPONSE TO CHEMOTHERAPY AND TREATING CANCER
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US20200216906A1 (en) * 2015-08-25 2020-07-09 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
DK3929305T3 (en) * 2015-12-01 2024-01-02 Lgc Clinical Diagnostics Inc Multiplex cellular reference materials
WO2017156154A1 (en) * 2016-03-08 2017-09-14 Rutgers, The State University Of New Jersey Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
SG11201900074WA (en) 2016-07-07 2019-02-27 Therachon Sas Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110191705A (zh) * 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7235676B2 (ja) 2017-05-17 2023-03-08 ザ ジェネラル ホスピタル コーポレイション 結節性硬化症の遺伝子治療
CN110195098A (zh) * 2019-05-10 2019-09-03 广州安必平医药科技股份有限公司 用于检测braf相关融合基因的探针组、试剂盒及其应用
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN112143815B (zh) * 2020-11-25 2021-02-26 江苏申基生物科技有限公司 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
IL304014A (en) 2020-12-30 2023-08-01 Tyra Biosciences Inc Indazole compounds as kinase inhibitors
JP2024509795A (ja) 2021-02-26 2024-03-05 タイラ・バイオサイエンシーズ・インコーポレイテッド アミノピリミジン化合物及びその使用方法
WO2024006897A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
WO2024006883A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264447B1 (it) 1993-05-14 1996-09-23 Ist Naz Stud Cura Dei Tumori Espressione di oncogeni derivati da ntrki in cellule di feocromocitoma pc12 ed utilizzo di questo sistema come screening di sostanze di
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US20020197679A1 (en) 2000-06-20 2002-12-26 Tang Y. Tom Novel nucleic acids and polypeptides
EP1423080A4 (en) 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
US7803382B2 (en) 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
EP1423415A4 (en) 2001-08-17 2005-04-06 Incyte Genomics Inc INTRA-CELLULAR SIGNAL MOLECULES
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20070010657A1 (en) 2002-09-13 2007-01-11 Rainer Klocke Cytoplasmic dynein heavy chain 1 genes, expression products, non-human animal model uses in human neurological diseases
US7838531B2 (en) 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
MY147449A (en) 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US7601532B2 (en) 2003-09-25 2009-10-13 Hisamitsu Pharmaceutical Co., Inc. Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
TWI281473B (en) * 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CA2555259A1 (en) 2004-02-27 2005-09-09 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
AU2006255101A1 (en) 2005-06-06 2006-12-14 Wyeth Anti-TrkB monoclonal antibodies and uses thereof
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
BRPI0722384A2 (pt) 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
EP2222321A4 (en) 2007-11-19 2013-02-13 Bionovo Inc THERAPY AGAINST CANCER WITH AN EXTRACT OF SCUTELLARIA BARBATA
WO2009103076A1 (en) 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
KR20230141927A (ko) 2010-12-30 2023-10-10 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US20130096021A1 (en) 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
KR20140114826A (ko) 2011-12-14 2014-09-29 시애틀 지네틱스, 인크. Fgfr 항체 약물 콘주게이트 (adcs) 및 그의 용도
MX365214B (es) * 2012-03-08 2019-05-27 Astellas Pharma Inc Nuevo producto de fusion de fgfr3.
AU2013295805B2 (en) * 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014036387A2 (en) 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
JP6117222B2 (ja) * 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20160010068A1 (en) 2013-02-22 2016-01-14 Boris C. Bastian Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets

Also Published As

Publication number Publication date
AU2020202555B2 (en) 2022-06-02
AU2022224823A1 (en) 2022-09-29
EP2914622B1 (en) 2023-06-07
US20160009785A1 (en) 2016-01-14
EP2914622A2 (en) 2015-09-09
EP4223770A3 (en) 2023-10-18
WO2014071419A2 (en) 2014-05-08
EP2914622C0 (en) 2023-06-07
WO2014071419A3 (en) 2014-09-12
EP4223770A2 (en) 2023-08-09
ES2949394T3 (es) 2023-09-28
AU2018203653A1 (en) 2018-06-14
CA2890346A1 (en) 2014-05-08
AU2013337264A1 (en) 2015-05-28
AU2013337264B2 (en) 2018-03-08
US11230589B2 (en) 2022-01-25
AU2020202555A1 (en) 2020-05-07
US20220169703A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
IL281148A (en) New and used KIF5B-RET fusion compounds
HK1214831A1 (zh) 新型融合分子及其應用
HK1214830A1 (zh) 新型 融合分子及其應用
HK1199023A1 (zh) 取代的苯並噻吩基-吡咯並三嗪及其用途
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1200822A1 (zh) 取代的聯吡啶胺及其用途
IL234234B (en) 2ang binding molecules
HK1210949A1 (zh) 組合及其用途
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
HK1210809A1 (zh) β己糖基轉移酶及其用法
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
ZA201503542B (en) Novel immunotherapeutic molecules and uses thereof
GB201208372D0 (en) Antibodies and uses thereof